Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation

Implementation Science

Emily A Arnold³  Stephen F Morin³  Wayne T Steward³  Tim Lane³  Patrick Hazelton³  Ja’Nina J Walker¹  Gabriel R Galindo² 

[1] Department of Psychology, University of San Francisco, 2130 Fulton Street, San Francisco, CA, 94117, USA;HIV Epidemiology Section, Office of AIDS, San Francisco Department of Public Health, 25 Van Ness Avenue, San Francisco, CA 94102, USA;Center for AIDS Prevention Studies, University of California at San Francisco, 50 Beale Street, Suite 1300, San Francisco, CA 94105, USA

关键词: Health disparities;    Qualitative research;    Pre-exposure prophylaxis (PrEP);    HIV/AIDS;    Male-to-female (MTF) transgender women;    Men who have sex with men (MSM);   

Others  :  813860
DOI  :  10.1186/1748-5908-7-116

 received in 2012-03-08, accepted in 2012-11-22,  发布年份 2012

【 摘 要 】

Background

An international randomized clinical trial (RCT) on pre-exposure prophylaxis (PrEP) as an human immunodeficiency virus (HIV)-prevention intervention found that taken on a daily basis, PrEP was safe and effective among men who have sex with men (MSM) and male-to-female transgender women. Within the context of the HIV epidemic in the United States (US), MSM and transgender women are the most appropriate groups to target for PrEP implementation at the population level; however, their perspectives on evidenced-based biomedical research and the results of this large trial remain virtually unknown. In this study, we examined the acceptability of individual daily use of PrEP and assessed potential barriers to community uptake.

Methods

We conducted semi-structured interviews with an ethnoracially diverse sample of thirty HIV-negative and unknown status MSM (n = 24) and transgender women (n = 6) in three California metropolitan areas. Given the burden of disease among ethnoracial minorities in the US, we purposefully oversampled for these groups. Thematic coding and analysis of data was conducted utilizing an approach rooted in grounded theory.

Results

While participants expressed general interest in PrEP availability, results demonstrate: a lack of community awareness and confusion about PrEP; reservations about PrEP utilization, even when informed of efficacious RCT results; and concerns regarding equity and the manner in which a PrEP intervention could be packaged and marketed in their communities.

Conclusions

In order to effectively reduce HIV health disparities at the population level, PrEP implementation must take into account the uptake concerns of those groups who would actually access and use this biomedical intervention as a prevention strategy. Recommendations addressing these concerns are provided.

【 授权许可】

   
2012 Galindo et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Katz MH: A pill a Day reduces risk for HIV infection: major study published in the New England journal of medicine demonstrates the effectiveness of a New HIV prevention tool, Pre-exposure prophylaxis (PrEP) [press release]. [http://www.sfdph.org/dph/files/newsMediadocs/2010PR/IprexPill.pdf] webciteSF Dept Pub Hlth 2010.
• [2]Grant RM, Lama JR, Anderson PL, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363(27):2587-2599.
• [3]Cahill S: [http:/ / www.fenwayhealth.org/ site/ DocServer/ PolicyFocus_PrEP_v7_02.21.12.pdf?do cID=9321] webcitePolicy Focus: Pre-exposure prophyalxis for HIV prevention: moving toward implementation. 2nd edition. Fenway Health Institute; 2012.
• [4]Morin SF: HIV pre-exposure prophylaxis: A once daily pill reduces risk in some groups but implementation will be challenging. BMJ 2012, 345:e5412.
• [5]Sax PE: [http:/ / www.thebodypro.com/ content/ 62932/ more-favorable-results-on-prep-but. html] webciteMore favorable results on PrEP, but…. the body Pro. 2011.
• [6]UNAIDS: Global facts & figures. Switzerland: Joint United Nations Programme on HIV/ AIDS, Geneva; 2009.
• [7]van Greiensven F, van Wijngaarden JW L, Baral S, Gruilich A: The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS 2009, 4:300-307.
• [8]Beyrer C, Baral SD, Walker D, Wirtz AL, Johns B, Sifakis F: The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency. Epidmiol Rev 2010, 32:137-151.
• [9]Centers for Disease Control and Prevention: [http://www.cdc.gov/nchhstp/newsroom/docs/Fact-Sheet-on-HIV-Estimates.pdf] webciteEstimates of new HIV infections in the United States. CDC Fact Sheet. 2008.
• [10]Alameda County Public Health Department: [http://www.hivccpc.org/] webciteCommunity collaborative working group presentation. Office of AIDS.
• [11]County of Los Angeles Department of Public Health: [http://www.lapublichealth.org/AIDS/] webciteEpidemiologic profile. Office of AIDS programs and policy.
• [12]San Francisco Department of Public Health: [http://www.sfhiv.org/data_reports.php] webciteSan Francisco HIV/ AIDS reports.
• [13]Herbst JH, Jacobs ED, Finlayson TJ, et al.: Estimating HIV prevalence and risk behaviors of transgender persons in the United States: A systematic review. AIDS Behav 2008, 12:1-17.
• [14]Office of National AIDS Policy: [http://www.whitehouse.gov/administration/eop/onap/nhas] webciteNational HIV/AIDS strategy for the United States. Washington, DC: White House; 2010.
• [15]Johnson WD, Hedges LV, Diaz RM: Interventions to modify sexual risk behaviors for preventing HIV infection in men who have sex with men. Cochrane Database Syst Rev 2003, 1:CD001230.
• [16]Mansergh G, Valdiserri RO, Yakovchenko V, Koh H: Aligning resources to fight HIV/ AIDS in the United States: funding to Sates through the US Department of Health and Human Services. J Acquir Immune Defic Syndr 2012, 59(5):516-522.
• [17]Clinton HR: [http:/ / globalhealth.kff.org/ ~/ media/ Files/ AIDS%202012/ 072312_plenary_transcript.pdf] webcitePlenary: ending the epidemic: turning the tide together. Washington, DC: XIX International AIDS Conference; 2012.
• [18]Padian NS, Buve A, Balkus J, Serwadda D, Cates W: Biomedical interventions to prevent HIV infection: evidence, challenges and way forward. Lancet 2008, 372:585-599.
• [19]Mayer KH, Bekker L, Stall R, Grulich AE, Colfax G, Lama JR: Comprehensive clinical care for men who have sex with men: an integrated approach. Lancet 2012, 380(9839):378-387.
• [20]Beyrer C, Sullivan PS, Sanchez J, Dowdy D, Altman D, Trapence G, Collins C, Katabira E, Kazatchkine M, Sidibe M, Mayer KH: A call to action for comprehensive HIV services for men who have sex with men. Lancet 2012, 380(9839):424-438.
• [21]Centers for Disease Control and Prevention: [http://www.cdc.gov/hiv/prep/] webcitePre-exposure prophylaxis (PrEP).
• [22]AIDS Vaccine Advocacy Coalition: A Quarterly update on HIV prevention research. Px Wire 2011, 4:4.
• [23]Grant RM, Lama JR, Anderson PL, et al.: Supplementary appendix (iPrEx study). N Engl J Med 2010. [NEJM online supplement]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079639/bin/NIHMS264954-supplement-Supplement1.pdf webcite
• [24]Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH: Preexposure antiretroviral prophylaxis attitudes in high-riksk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 2009, 50:77-83.
• [25]Liu AY, Kittredge PV, Vittinghoff E: Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008, 47:241-247.
• [26]Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee S, Leibowitz AA: Motivators, concerns and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care 2011, 23(9):1136-1145.
• [27]Krakower SD, Mimiage MJ, Rosengberger JG, Novak DS, Mitty JA, White JM, Mayer KM: Limited awareness and Low immediate uptake of Pre-exposure prohylaxis among Men Who have Sex with Men using an internet social networking site. PlosOne 2012, 7(3):e33119.
• [28]Holt M, Murphy DA, Callander D, Ellard J, Rosengarten M, Kippax SC, de Wit JB: Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect 2012, 88(4):258-263.
• [29]Davis M, Hart G, Bolding G, Sherr L, Elford J: E-dating, identity and HIV prevention: theorising sexualities, risk and network society. Sociol Health Illn 2006, 28(4):457-478.
• [30]Greenspan NR, Aguinaldo JP, Husbands W, Murray J, Ho P, Sutdhibhasilp N, Cedano J, Lau C, Gray T, Maharaj R: "It's not rocket science, what I do": Self-directed harm reduction strategies among drug using ethno-racially diverse gay and bisexual men. Int J Drug Policy 2011, 22(1):56-62.
• [31]Ridge D, Ziebland S, Anderson J, Williams I, Elford J: Positive prevention: contemporary issues facing HIV positive people negotiating sex in the UK. Soc Sci Med 2007, 65(4):755-770.
• [32]Zablotska IB, Holt M, Prestage G: Changes in gay men's participation in gay community life: implications for HIV surveillance and research. AIDS Behav 2012, 16(3):669-675.
• [33]Denzin NK, Lincoln YS: Strategies of qualitative inquiry. Thousand Oaks, CA: Sage Publications; 1998.
• [34]Miles MB, Huberman AM: Qualitative data analysis. 2nd edition. Thousand Oaks, CA: Sage; 1994.
• [35]Janz NK, Becker MH: The health belief model: a decade later. Health Educ Q 1984, 11(1):1-47.
• [36]Stokols D: Translating social ecological theory into guidelines for community health promotion. Am J Health Promot 1996, 10(4):282-298.
• [37]Godin G, Kok G: The theory of planned behavior: a review of its applications to health-related behaviors. Am J Health Promot 1996, 11(2):87-98.
• [38]Patton MQ: Qualitative research and evaluation methos. 3rd edition. Thousand Oaks, CA: Sage; 2002.
• [39]Muhr T: Atlas.ti for windows. Berlin: Scientific Software Development; 1997.
• [40]Smith DK, Grohskopf LA, Black RJ, et al.: Antiretroviral postesposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: Recommendations from the US Department of Health and Human Services. MMWR 2005, 54(RR02):1-20.
• [41]Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN: Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep 2011, 8:62-72.
• [42]Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K: Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr 2010, 55(1):8-13.
• [43]Myers GM, Mayer KH: Oral preexposure anti-HIV prophylaxis for high-risk US populations: current considerations in light of new findings. AIDS Patient Care STDS 2011, 25:63-71.
• [44]Golub SA, Kowalczyk W, Weinberger CL, Parsons JT: Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 2010, 54(5):548-555.
• [45]HIV Prevention Trials Network: [http://www.hptn.org/research_studies/hptn067.asp] webciteThe ADAPT study: a phase II, randomized, open-label, pharmacokinetic and behavioral study of the Use of intermittent oral emtricitabine/tenofovir disoproxil fumarate Pre-exposure prophylaxis (PrEP).
• [46]Cohen SE: San Francisco PrEP demonstration project. San Francisco Department of Public Health, HIV Prevention and Planning Council; 2011. http://sfhiv.org/documents/0908HPPCTalkPrEP.pdf webcite]
• [47][http://iPrExole.com/index.html] webciteIPrEx. IPrEx open label extension.
• [48]Buchbinder SF, Liu A: Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 2011, 15:S72-S79.
• [49]Coates TJ, Richter L, Caceres C: Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008, 372(9639):669-684.
• [50]Grant RM: [http://juno.cumc.columbia.edu/pi/videos/pill-day-keep-hiv-away] webciteA pill a day to keep HIV away. Columbia University: HIV Center Ground Rounds;
• [51]Parker R: Empowerment, community mobilization and social change in the face of HIV/ AIDS. AIDS 1996, 10(Suppl 3):S27-S31.
• [52]Tedrow VA, Zelaya CE, Kennedy CE, et al.: No "magic bullet": exploring community mobilization strategies used in an multi-site community based randomized controlled trial: project accept. AIDS Behav. 2012 Jul, 16(5):1217-1226.
• [53]Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH: Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/ AIDS Rep 2010, 7:210-219.
• [54]Paltiel AD, Freedberg KA, Scott CA, et al.: HIV preexposure prophylaxis in the united states: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009, 48(6):806-815.
• [55]Gilead Sciences, Inc: U.S. Food and drug administration approves Gilead's truvada® for reducing the risk of acquiring HIV [press release]. Gilead. 2012. http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1715013&highlight webcite=
• [56]Juusola JL, Brandeau ML, Owens DK, Bendavid E: The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 2012, 156(8):541-550.
• [57]Leibowitz AA, Parker KB, Rotheram-Borus MJ: A US policy perspective on oral preexposure prophylaxis for HIV. Am J Pub Hlth 2011, 101(6):982-985.
• [58]Sullivan PS, Carballo-Diéguez A, Coates T, Goodreau SM, McGowan I, Sanders EJ, Smith A, Goswami P, Sanchez J: Successes and challenges of HIV prevention in men who have sex with men. Lancet 2012, 380(9839):388-399.
• [59]Kippax S, Stephenson N: Beyond the distinction, between biomedical and social dimensions of HIV: prevention through the lens of a social public health. Am J Public Health 2012, 102(5):789-799.
• [60]Kippax S, Stephenson N: Kippax and Stephenson Respond. Am J Public Health 2012, 102(9):e9-e10.
• [61]Arnold EA, Hazelton P, Lane T, Christopoulos KA, Galindo GR, Steward WT, Morin SF: A qualitative study of provider thoughts on implementing Pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One 2012, 7(7):e40603.